Awada et al. [49] performed a clinical trial for dabrafenib and the MEK inhibitor, trametinib [50], in combination with HCQ, in advanced BRAFV600-mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Here, BRAF is linked to melanoma.